|
Study | Number of patients | 1st year survival (%) | Median overall survival (m) | Responding patients/ratio (%) | Median overall survival of responding patients (m) | Median overall survival of nonresponding patients (m) | Reference |
|
Brain gliomas | 27 | 86.2 | 23.6 | 43 | 66.2 | 18.2 | [51, 52] |
Brain lioma study, phase II | 140 | 71.7 | | | | | |
Astrocytoma | 40 | | 25.8 | 80 | 40.2 | 20.2 | [53, 54] |
Glioblastoma | 92 | | 16 | 73 | 21.*9 | 13.1 |
Diffuse astrocytoma | 8 | | 52.9 | | | | |
Glioma (WHO IV) study, phase II, prospective, two arms | 45 | | 15 | | | | |
Passive arm | 36 | 40 | 11 | | | | [55, 56] |
Active arm | 9 | 65 | 14.5 | 43 | 66.2 | 18.2 | |
Recurrent glioblastoma study, phase II | 19 | 68.0 | 21.8 | 59 | 32.6 | 12.4 | [57] |
Glioma study, phase II | 36 | 60.0 | | | | | |
Astrocytoma | 9 | | 106 | | | | [58] |
Glioblastoma | 27 | | 20 | | | | |
Glioma study, phase II | 179 | | | | | | |
Astrocytoma | 53 | 100 | 103 | | | | [59] |
Glioblastoma | 126 | 76 | 16 | | | | |
Advanced, relapsed brain gliomas, phase II | 12 | | 10 | 25 | | | [60] |
Advanced, relapsed brain gliomas, phase II | 24 | 55 | 12 | 25 | | | [61] |
Brain glioma WHO III-IV, phase I, safety prospective | 24 | | | | | | [62–65] |
Metastatic brain tumors study, phase II | 15 | 90.0 | 46.2 | 73 | 48.2 | 16.1 | [60] |
Head and neck study, phase II | 64 | 92.2 | 26.1 | | | | [55, 66] |
Bone-metastases, monotherapy, phase II | 6 | 100 | 40.1 | | | | [55, 66] |
Refractory bone-metastases study, phase II | 11 | | | 90.9 | | | [67] |
Kidney cancer study, phase II | 39 | 84.6 | 35.9 | 48 | 78.4 | 33.7 | [55, 66] |
Urinary bladder cancer study, phase II | 18 | 85.0 | 36.5 | 73 | 42.0 | 22.6 | [55] |
Nonsmall cell lung cancer meta-analysis | 311 | | | | | | |
Passive arm | 53 | 26.5 | 14 | | | | |
Active arm | 258 | 67.0 | 15.8 | 21 | 53.4 | 18.1 | [68] |
Nonadvanced (WHO < III) | 77 | | 11 | 17 | | | |
Advanced (WHO ≥ III) | 140 | | 14.7 | 88 | | | |
Small-cell lung cancer | 28 | | | | | | |
Passive arm | 9 | 29 | | | | | [69] |
Active arm | 19 | 58 | | | | | |
Lung carcinoma study, phase II | 61 | 67.2 | 16.4 | | | | [55, 70] |
Breast cancers | 103 | 97.1 | 52.1 | 45 | 274.8 | 10.9 | [55, 66] |
Soft tissue sarcoma study, phase II | 16 | 100 | 35.9 | 31 | 115.3 | 31.3 | [55] |
Esophagus study, phase II | 12 | 41.7 | 28.5 | 35 | 29.4 | 8.5 | [55, 71] |
Esophagus study, phase II | 7 | | 6.8 | 100 | | | [72] |
Liver metastases from various origin, phase II | 25 | | 20.5 | | | | [73] |
Liver metastases from various origin, comparative study, phase II | 28 | | | | | | |
With radiotherapy | 16 | | | 81 | | | [67] |
With chemotherapy | 8 | | | 38 | | |
Monotherapy | 4 | | | 25 | | | |
Liver metastasis form colorectal origin, phase II | 80 | 86.0 | 24.1 | | | | |
Passive arm | | 53 | 11 | | | | |
Active arm | 80 | 91 | 24.1 | | | | [74] |
With chemotherapy | 30 | 80 | 21.5 | | | | |
Monotherapy | 50 | 92 | 24.4 | | | | |
Liver metastasis form colorectal origin, phase II | 15 | | 23 | 80 | | | [75] |
Liver metastasis form colorectal origin, phase II | 22 | | 28 | | | | [76] |
Liver metastasis | 29 | | | 86 | | | |
Liver metastasis form colorectal origin, phase II | 30 | | 22 | | | | [77] |
Pancreas tumor study, phase II | 26 | 46.2 | 11.6 | | | | [78] |
Pancreas tumor study, phase II | 107 | | | | | | |
Passive arm | 34 | | 6.5 | | | | [70] |
Active arm | 73 | 52.1 | 9.93 | 58 | 25.5 | 8.4 | |
Pancreas tumor study, phase II | 30 | 31.0 | | 41 | 34.4 | 5.6 | [79, 80] |
Pancreas tumor study, phase II | 42 | 52.4 | 12.3 | | | | [81] |
Pancreas tumor study, phase II | 13 | 40.0 | 11.9 | | | | [82] |
Stomach cancer study, phase II | 68 | 58.9 | 14.4 | | | | [55] |
Colorectal cancer () | 218 | 84.9 | 28.5 | | | | |
Sigma | 12 | | | 34.1 | | | [55, 66] |
Rectum | 92 | | | 57.1 | 58 | 21 |
Colon | 114 | | | 44.2 | 109.8 | 23.2 | |
Colon cancer study, phase II, prospective, three arms, randomized | 154 | | | | | | [83, 84] |
Clifford TCM | 53 | | | 75 | | |
Monotherapy | 50 | | | 81 | | | |
Combined therapy | 51 | | | 91 | | | |
Rectum cancer study, Inoperable→operable, phase II | 7 | | | 71 | | | [72] |
Rectal cancer, nonoperable, phase II | 65 | | | 96 | | | [85] |
Pelvic gynecological cancer studies, phase II | 74 | | | | | | |
Cervix | 38 | 86.8 | 27.6 | 25 | 63.5 | 20.9 | [86] |
Ovary | 27 | 100 | 37.8 | 67 | 132.7 | 19.4 |
Uterus | 9 | 100 | 61.5 | 62 | 68.5 | 32.0 | |
Ovary, advanced, relapsed | 26 | | | | | | [87] |
Heavily pretreated | 13 | | 14.3 | | | | |
Not heavily pretreated | 13 | | 27 | | | | |
Prostate cancer study, phase II | 18 | 88.9 | 38.8 | 72 | 53.4 | 7.6 | [71] |
|